Walmart hit by four food recalls in two months: Which products are affected?
As the world's largest retailer, Walmart sees nearly 95% of Americans shop in its stores twice yearly, reports AiTechtonic. The company says it prioritizes safety: 'We act fast to stop sales and pull recalled items.'
According to Newsweek, recalls are handled by Walmart's food safety teams. Products are blocked from shelves and online orders immediately. The FDA monitors compliance.
Walmart assures customers it works with regulators to 'provide safe, compliant products.' Shoppers are urged to check Walmart's website for updates.
ALSO READ | Microsoft to CrowdStrike: These tech firms lead 2025 layoffs as 50,000 jobs vanish in 5 months
In this context, a statement on Walmart's website reads, 'Walmart and Sam's Club are committed to the health and safety of our customers and members and to providing products that are safe and compliant, all supported by our health and wellness, product safety, and food safety professionals. In the event of a product recall, we work swiftly to block the item from being sold and remove it from our stores and clubs.'
The first in line for the recall was baked beans. Vietti Food Group of Nashville, Tennessee, issued a major recall of 4,515 cases of its Yellowstone Brown Sugar Molasses Baked Beans (15 oz.) due to the presence of undeclared soy. This recall was initiated on May 2 this year. The press release by the Vietti Food Group surrounding this issue reads, "Vietti Food Group is recalling 4,515 cases of its Yellowstone Brown Sugar Molasses Baked Beans (15 oz.) due to the presence of undeclared soy. Individuals with an allergy or severe sensitivity to soy risk serious or life-threatening allergic reactions if they consume this product."
However, no illness has been reported among consumers yet. Those who have purchased the item are requested to return it to the respective stores to receive a full refund.
Then comes celery sticks, which the Duda Farm Fresh Foods, Inc., based in Oxnard, California, has issued an advisory about. As per Newsweek, the recalled product is a 4-count bundle pack of 4-inch/1.6 oz Marketside Celery Sticks, sold at Walmart. This advisory by Duda Farm Fresh Foods was issued on April 10 this year, sometime before the baked beans issue hit the streets.
Other food items hit by food recalls include the likes of
Among the Lean Cuisine and frozen meals, the affected products include:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Fitness tips: Smart and easy ways you can sneak in more movement in your day to day life
Most of us already know that exercise is essential for staying healthy, but knowing and doing are two very different things. Between work deadlines, family responsibilities, and the temptation to unwind in front of a screen, it's easy to let movement slip to the bottom of the list. Tired of too many ads? go ad free now The U.S. Centers for Disease Control and Prevention (CDC) reports that many Americans spend six to eight hours each day sitting- a habit tied to higher risks of early death, heart disease, type 2 diabetes, and obesity. And while those risks can sound overwhelming, the good news is that you don't always need a gym membership or a strict workout plan to protect your health. Even short, intentional bursts of movement throughout the day can counteract much of the damage caused by long periods of sitting, giving your body the push it needs to stay strong and resilient over time. Go grocery shopping instead of ordering online Ordering groceries is convenient, but it robs you of an easy way to stay active. Walking around the store, pushing a cart, reaching for items, and carrying bags home all count as physical activity. Even a 20-minute grocery run can add steps and light resistance work into your day. Bonus: you're more likely to make fresher, healthier choices when you shop in person. Try leg exercises while you brush your teeth Two minutes of brushing, twice a day, is a perfect time to work your lower body. Do calf raises, squats, or lunges while you brush. These small moves improve balance, strengthen muscles, and keep your legs active without needing extra time in your schedule. If possible, schedule work meetings outside the office Walking meetings aren't just for Silicon Valley executives. If you can take a meeting while strolling around the block or a nearby park, you'll log extra steps and get fresh air. Walking side-by-side can also make conversations flow more easily, sparking creativity and better ideas. Tired of too many ads? go ad free now Walk to nearby places If your destination is less than a mile away, consider walking instead of driving. It saves gas, reduces your carbon footprint, and gives your body a natural dose of movement. Over a week, these short walks can add up to hours of activity. Use a desk treadmill or walking pad during your workday Many people now work from home or in flexible offices. A treadmill desk lets you walk at a slow pace while answering emails or attending virtual meetings. Even an hour of gentle walking during the workday can improve circulation, energy, and focus. Skip the elevator and take the stairs It's a classic tip for a reason. Climbing stairs works your legs, glutes, and core while getting your heart rate up. If you work on a high floor, try taking the stairs for the first few flights and then using the elevator the rest of the way. Set a timer and walk for five minutes every hour Sitting for long stretches can cause stiffness and reduce blood flow. Setting a timer to stand up and walk, even for just five minutes, helps counter those effects. Walk to the kitchen, around your home, or simply pace while on a phone call. Invest in a standing desk and use it Standing isn't the same as exercising, but it engages more muscles than sitting. According to a 2024 study, desk-bound workers have a 16% higher risk of dying early from all causes and a 34% higher risk of dying from cardiovascular disease. Switching between sitting and standing throughout the day keeps your body more active and alert.
The Print
10 hours ago
- The Print
Indian doctors more confident about oestrogen therapy for menopause as USFDA may scrap black box warning
The move came after the findings of a Women's Health Initiative (WHI) study—the largest-ever randomised controlled trial of hormone therapy in 2002—went public. The study found a combined oestrogen-progestin therapy linked to a rise in heart attacks and strokes, and a slightly elevated risk of breast and endometrial cancers. The USFDA, in 2003, mandated a black box warning—the highest level of warning associated with approved drugs when proven to be associated with serious or life-threatening adverse events—on all menopause treatments containing oestrogen, regardless of form or absorption rates. New Delhi: The United States Food and Drug Administration (USFDA) has declared its plan to remove the currently mandated, strictest health warning on oestrogen replacement therapies. The development has triggered a debate around the treatment, once widely used to manage menopausal symptoms but later linked to harmful side effects, such as cancer. However, the FDA panel, which held a discussion telecast publicly last month, was of the view that at least local oestrogen therapy, such as vaginal cream, is safe and should not carry the same warnings as systemically delivered oestrogen via patches or pills taken orally. The panel suggested that the risks associated with hormone replacement therapy (HRT) likely were overstated. The FDA has now invited submission of broad, public comments on the risks and benefits related to menopause hormone therapy, including 'data that could support updates to the labelling of such products'. Typically occurring between the ages of 45 and 55, menopause is the cessation of menstruation and the decline in ovarian function. This biological process comes with hormonal fluctuations, mainly the lowering of oestrogen and progesterone levels, which can lead to a variety of physical and psychological symptoms. A hallmark symptom of menopause is hot flashes, characterised by sudden waves of heat, flushing, and sweating, often accompanied by palpitations and feelings of anxiety. Additionally, many women experience night sweats while the drop in oestrogen levels has links to a marked rise in mood swings and behavioural changes, vaginal dryness, adverse bone health, cardiovascular events, and the risk of breast cancer. HRT had been a common approach since the 1970s to manage menopausal symptoms by supplementing the body with oestrogen, progesterone, or both. However, since 2000, following the WHI findings, most doctors and patients worldwide have been cautious in recommending or using it, and its popularity has dramatically dropped. In India, where HRT is available in the form of pills, vaginal creams, and topical cream applied on the arms, but no implants or patches, like in the US, there is no country-specific box warning, which is mandatory for the products in India. India never updated the official regulatory stance to reflect the advanced risk-benefit understanding associated with the treatment. However, experts maintained that clinicians had been hesitant in prescribing it. Now, many, including those in India, believe the situation will change. 'I am glad at the development concerning the warning status related to HRT for menopause,' Dr Archana Dwiwedi, the chair of the mid-life committee in the Federation of Obstetric and Gynaecological Societies of India (FOGSI), told ThePrint. A large number of women undergoing menopause or post-menopause can benefit majorly from HRT but remain deprived of it, mainly on account of evidence that may now be outdated, she said, adding that current scientific understanding is that HRT's benefits for most women far outweigh the risks. Also Read: What is the 'women's health gap' and how to close it 'Evolving' evidence In 1991, the National Institutes of Health in the US launched the WHI, a $625 million, long-term, randomised controlled study to investigate ways to prevent the leading causes of death and disability in postmenopausal women. The WHI recruited 1,61,808 postmenopausal women aged 50 to 79 for its study, and over 68,000 participated in one of three clinical trial arms—hormone therapy, diet modification, or calcium and vitamin D supplementation. The hormone therapy trial, intended to last nine years, would evaluate the long-term health impacts of the two most common HRT regimens at the time—conjugated equine estrogen (CEE-oestrogen derived from the urine of pregnant mares) plus progestin, or synthetic progesterone for women with a uterus and CEE alone for others who underwent a hysterectomy and no longer had a uterus. Eleven years later, the NIH announced that it was stopping the oestrogen-plus-progestin arm of the trial early, citing increased rates of blood clots, stroke, heart attacks, and breast cancer in women taking the combined hormone therapy. These findings led to a dramatic shift in the usage pattern of HRT globally, with a large number of patients and doctors abandoning it overnight. However, experts now say the WHI findings have since come under intense scrutiny, and an understanding has evolved that the results, which profoundly impacted the use of HRT, could have been skewed. For instance, the trial participants were old—63-year-olds on average—who in any case have a high baseline risk for cardiovascular conditions. Also, a follow-up study, which came out in 2024, concluded that HRT is safe and beneficial for most healthy women with bothersome menopause symptoms if they start it in the years shortly after menopause begins. 'The latest versions of HRT are also far safer and can make life easier for a high percentage of women, who face bothersome health challenges in the menopause stage, which severely affects their quality of life,' Dwiwedi said. There, however, are some sceptics too. 'I suspect the pharmaceutical industry pushed the latest FDA development. While the FDA panel batting for warning labels in the HRT shared a lot of anecdotal evidence to suggest they are safe, why was there not any scientific presentations to back those claims?' asked a gynaecologist with AlIMS Delhi, who did not wish to be named. However, while there is no clarity on whether the FDA will remove the requirement of black box warnings on all HRT for menopause, several of the panel members made a strong case for at least local oestrogen therapies, with comparatively low level of oestrogen, for symptoms such as vaginal dryness and urinary issues, as opposed to systemic therapies in the form of pills and implants. Some Indian clinicians agree with this argument. Vaginal oestrogen cream, mainly prescribed based on requirement, is not for a systemic replacement of oestrogen, but for local reasons, such as dryness or burning sensation, or poor urinary control or poor comfort level in terms of intercourse, said gynaecologist Dr Hemanandini Jayaraman from Manipal Hospital in Bengaluru. She said that the absorption of vaginal creams into the body is negligible, so no enhanced risk or risk factors are associated with the creams, which women generally use for local reasons. 'As far as continuing the vaginal application is concerned, if a patient gets symptomatic relief, which is extremely good, it can be safely pursued for a longer duration of time,' the clinician added. However, she also maintained that HRT, even in the form of oral prescription, could be safe provided there is regular monitoring of the users. Also Read: Over 50% of Indian women are anaemic. We need health literacy, support groups: Shabana Azmi Attitudes towards HRT in India India has nearly 15 crore women estimated to be postmenopausal, and roughly 30-40 percent of them could be considered potential candidates for HRT. 'These are women who are symptomatic and have no contraindications, such as prior hormone-sensitive cancers or high clotting risk, typically considered suitable candidates for HRT,' the Federation of Obstetrics & Gynaecological Societies of India (FOGSI) member said. However, according to estimates, less than five percent of women receive HRT. Currently, India follows a global prescription for norms for hormone therapy, including the USFDA as well as European guidelines. And while there is no equivalent to the FDA's black box warning on systemic risks like breast cancer, stroke, or clots here, the Indian drug monographs and medical literature still describe side effects for estrogen therapy, such as deep vein thrombosis, hypertension, breast and endometrial cancer, and dementia. Moreover, the guidelines from Indian expert groups mirror international concerns about systemic oestrogen use in women with certain risk factors, usually after age 60 or more than 10 postmenopause years, pointed out Dr Sweta Kumar, a gynaecologist and obstetrician with Surya Mother and Child Super Speciality Hospital in Pune. While many gynaecologists in India are aware of HRT and do prescribe it to some patients, a significant number are hesitant or prefer alternative options. Younger or less experienced clinicians tend to be more cautious, and alternative therapies are still quite common in practice, Kumar said. According to the 2025 national cross-sectional survey of 514 young Indian obstetricians-gynaecologists, the combined oestrogen-progestin therapy for vasomotor symptoms was recommended by 83 percent of the practitioners with three years' or below-three years' experience. When their experience range was seven to 10 years, fewer practitioners, 77 percent, recommended it. Moreover, younger doctors (0–3 years) were found less likely to support early initiation of therapy—30 percent of them—compared to more experienced ones—49 percent of them. A large number of patients also find HRT risky and are hesitant to use it, Dr N.S. Saradha, a senior gynaecologist with SIMS Hospital in Chennai, underlined. 'Women experiencing early or surgical menopause, accelerated bone loss, and high risk of osteoporosis benefit the most from HRT. I hope with the evolving understanding around HRT, both doctors and patients can make informed decisions on its usage,' Saradha said. (Edited by Madhurita Goswami) Also Read: AI can aid in early, precise detection of breast cancer, show results of 1st randomised trial
Time of India
11 hours ago
- Time of India
Now you don't need reading glasses, new FDA-approved eye drops can sharpen near vision
The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz Therapeutics developed this aceclidine-based treatment. Vizz narrows the pupil, increasing focus. Clinical trials showed results within 30 minutes, lasting up to 10 hours. Common side effects include dim vision and eye irritation. Now you don't need reading glasses as FDA approves Vizz eye drops to sharpen near vision for up to 10 hours Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The US Food and Drug Administration has approved Vizz, a once-daily prescription eye drop that can temporarily improve age-related blurry near vision, or presbyopia, for up to 10 by California-based Lenz Therapeutics , Vizz is the first FDA-approved aceclidine-based treatment for presbyopia in the United States. It is expected to be available in clinics and pharmacies starting in is a common condition affecting most adults over 40, making it harder to focus on close objects. People often rely on reading glasses or contact lenses to see clearly at close works by using aceclidine to narrow the pupil, creating a 'pinhole effect' similar to a camera lens adjustment. This increases depth of focus without blurring distance vision or causing the 'zoomed-in' effect seen with some previous late-stage clinical trials, results appeared within 30 minutes, peaked at three hours and lasted for as long as 10 hours. According to the company, 71 percent of participants could read at least three more lines on a near-vision chart without loss of distance clarity.'This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision,' said Vizz clinical investigator Marc Bloomenstein, from Schwartz Laser Eye Care Center in Scottsdale, Ariz., in a statement.'I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' side effects reported in trials included temporary dim vision, mild eye irritation and headaches. The FDA advises patients to avoid driving or operating heavy machinery until vision clears after using the drops and to be cautious in low-light Therapeutics says the drops will be available by prescription only.
